Why BSA and Cumulative Dose Matter Together
For some chemotherapy drugs, even if each individual dose is safe, the total amount accumulated over repeated cycles can sharply increase the risk of organ-specific side effects like heart or lung damage once it crosses a certain threshold. This tool calculates BSA using the Mosteller formula, multiplies your per-cycle dose (mg/m²) by the number of cycles to get your cumulative dose, and compares it to a commonly cited reference limit to give you a rough risk range.
Common Cumulative Limit Examples
Doxorubicin-class drugs are widely cited as carrying a significantly increased risk of cardiotoxicity (heart failure) once cumulative dose exceeds 550 mg/m², making it a common clinical reference. Epirubicin-class drugs are discussed in a somewhat higher range of 400-900 mg/m², but this tool uses the more conservative 400 mg/m² as an example. Actual limits vary by drug combination and patient condition.
Factors Beyond Dose That Affect Risk
Even at the same cumulative dose, actual side effect risk varies significantly with age, pre-existing heart/liver/kidney conditions, concurrent chest radiation therapy, and combination with other cardiotoxic drugs. The percentage this tool provides is just one reference indicator and cannot replace a comprehensive risk assessment.
Important Notes
This tool offers general educational reference information only. Whether to continue chemotherapy or adjust dosing must always be decided by your oncologist based on echocardiograms and other regular test results. Never stop or continue treatment based on this result alone.
Frequently Asked Questions
Some chemo drugs carry sharply rising organ toxicity risk once total dose exceeds a threshold. Doxorubicin-class drugs commonly cite 550 mg/m².
No. It only calculates cumulative dose as a percentage of a reference threshold. Actual decisions are made by your medical team.
Age, existing heart/liver/kidney conditions, and concurrent radiation therapy all influence risk, so dose alone can't determine it.